Generalized peripheral lymphadenopathy in a patient treated for chronic HCV infection

Ferreira, Carlos Noronha; Barjas, Elídio; Correia, Luís; Tavares, Luís; Ferreira, Cristina; Serejo, Fátima; Moura, Miguel Carneiro de; Monteiro, Estela

doi:10.1038/ncpgasthep1176

Nat Rev Gastroenterol Hepatol

2008

DOI: 10.1038/ncpgasthep1176

|View full text |Cite

Generalized peripheral lymphadenopathy in a patient treated for chronic HCV infection

Carlos Noronha Ferreira

Elídio Barjas

Luís Correia

et al.

Abstract: Standard antituberculosis treatment with isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months, followed by isoniazid and rifampicin for 7 months.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2016

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the extent of our knowledge, at least 16 Tb cases during or soon after interferon-based hepatitis C therapy in non-HIV patients were reported in 15 articles so far, some of them describing severe outcomes of tuberculosis reactivation. 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 …”

mentioning

confidence: 99%

High incidence of tuberculosis in patients treated for hepatitis C chronic infection

Uehara

Emori

Perez

et al. 2016

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

Brazil is one of the 22 countries that concentrates 80% of global tuberculosis cases concomitantly to a large number of hepatitis C carriers and some epidemiological risk scenarios are coincident for both diseases. We analyzed tuberculosis cases that occurred during α-interferon-based therapy for hepatitis C in reference centers in Brazil between 2001 and 2012 and reviewed their medical records. Eighteen tuberculosis cases were observed in patients submitted to hepatitis C α-interferon-based therapy. All patients were human immunodeficiency virus-negative. Nine patients (50%) had extra-pulmonary tuberculosis; 15 (83%) showed significant liver fibrosis. Hepatitis C treatment was discontinued in 12 patients (67%) due to tuberculosis reactivation and six (33%) had sustained virological response. The majority of patients had a favorable outcome but one died. Considering the evidences of α-IFN interference over the containment of Mycobacterium tuberculosis, the immune impairment of cirrhotic patients, the increase of tuberculosis case reports during hepatitis C treatment with atypical and severe presentations and the negative impact on sustained virological response, we think these are strong arguments for latent tuberculosis infection screening before starting α-interferon-based therapy for any indication and even to consider IFN-free regimens against hepatitis C when a patient tests positive for latent tuberculosis infection.

show abstract

mentioning

confidence: 99%

High incidence of tuberculosis in patients treated for hepatitis C chronic infection

Uehara

Emori

Perez

et al. 2016

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

Adenitis tuberculosa tras tratamiento con éxito de hepatitis C

Velasco¹,

González²

2011

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

Sarcoidosis and hepatitis C: clinical description of 11 cases

Faurie

Broussolle

Zoulim³

et al. 2010

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Clinical manifestations of sarcoidosis may occur in HCV patients, especially during or after treatment with immunotherapy. In our experience, sarcoidosis triggered by antiviral therapy was more frequent after completion of therapy, but concording with literature, presented a benign outcome. In sarcoidosis, seen in treatment-naive HCV patients, systemic corticosteroids had to be used more often and outcome was less favourable.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Generalized peripheral lymphadenopathy in a patient treated for chronic HCV infection

Abstract: Standard antituberculosis treatment with isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months, followed by isoniazid and rifampicin for 7 months.

Cited by 3 publications

References 11 publications

High incidence of tuberculosis in patients treated for hepatitis C chronic infection

High incidence of tuberculosis in patients treated for hepatitis C chronic infection

Adenitis tuberculosa tras tratamiento con éxito de hepatitis C

Sarcoidosis and hepatitis C: clinical description of 11 cases

Contact Info

Product

Resources

About